• Trendlyne logo
  • Markets
  • Alerts
  • F&O
  • MF
  • Reports
  • Screeners
  • Subscribe
  • Superstars
  • Portfolio
  • Watchlist
  • Insider Trades
  • Results
  • Data Downloader
  • Events Calendar
  • What's New
  • Explore
  • FAQs
  • Widgets
More
    Search stocks
    IND USA
    IND
    IND
    IND
    USA
    • Stocks
    • Futures & Options
    • Mutual Funds
    • News
    • Fundamentals
    • Reports
    • Corporate Actions
    • Alerts
    • Shareholding
    logo
    Mankind Pharma Ltd.
    08 Jan 2025
    Board Meeting
    2549.20
    -0.58%
    Complete Circle Capital's wealth management arm raises $3 million funding from Mankind Pharma promoters
    Complete Circle Capital's wealth management arm raises $3 million funding from Mankind Pharma promoters
    livemint
    Complete Circle Capital's wealth management division, established by Gurmeet Chadha and Kshitiz Mahajan in 2015, will utilize the funds to speed up its growth and expansion strategies.
    Copy LinkShare onShare on Share on Share on
    Mankind Pharma Ltd. is trading above all available SMAs
    Mankind Pharma Pledges 56% Stake In Subsidiary Bharat Serums
    NDTV Profit | 07 Jan 2025
    logo
    Dr. Reddy's Laboratories Ltd.
    08 Jan 2025
    1224.20
    0.43%
    Dr Reddy's share price jumps 4% on Nuvama's upgrade to buy; brokerage sees potential despite risks from Revlimid expiry
    Dr Reddy's share price jumps 4% on Nuvama's upgrade to buy; brokerage sees potential despite risks from Revlimid expiry
    livemint
    Dr Reddy's share price rose nearly 4% after Nuvama Institutional Equities upgraded its rating to 'Buy' with a target of 1,553, highlighting proactive strategies to mitigate the impact of Revlimid's patent expiration in 2026, despite a 9.35% drop in net profit for September 2024.
    Copy LinkShare onShare on Share on Share on
    KRChoksey increased Accumulate price target of Dr. Reddy's Laboratories Ltd. to 1324.0 on 13 May, 2025.
    Dr. Reddy's pops 4% after Nuvama upgrades to 'Buy'; arm sells US mfg unit
    Business Standard | 08 Jan 2025 1 more
    Dr. Reddy's Gets 'Buy' Upgrade From Nuvama On Plans To Mitigate Key Patent Loss
    NDTV Profit | 08 Jan 2025
    logo
    Dr. Reddy's Laboratories Ltd.
    08 Jan 2025
    1224.20
    0.43%
    Markets fall on global cues; US jobs data dampens rate cut hopes
    Business Line
    While healthcare and energy stocks, such as Dr. Reddy's Laboratories and ONGC, showed resilience, companies like Trent faced notable losses.
    Copy LinkShare onShare on Share on Share on
    Number of FII/FPI investors decreased from 927 to 911 in Mar 2025 qtr
    logo
    Alkem Laboratories Ltd.
    07 Jan 2025
    5259.00
    -1.22%
    Alkem Laboratories To Sell Pithampur Unit For Rs 149 Crore
    Alkem Laboratories To Sell Pithampur Unit For Rs 149 Crore
    NDTV Profit
    The company has entered into a business transfer agreement with Rubicon Research Ltd. on Jan. 6, 2025, to sell the facility on a slump sale basis.
    Copy LinkShare onShare on Share on Share on
    Alkem Laboratories L.. has an average target of 5278.50 from 2 brokers.
    logo
    Laurus Labs Ltd.
    07 Jan 2025
    593.25
    -2.32%
    Laurus Labs hits 2-yr high on hopes of healthy earnings; up 44% in 3 months
    Business Standard
    The board of directors of Laurus are scheduled to meet on January 24 to announce the financial results of the company for the quarter ended December 31, 2024.
    Copy LinkShare onShare on Share on Share on
    Laurus Labs Ltd.'s price crossed below 50Day SMA today
    logo
    Biocon Ltd.
    07 Jan 2025
    332.50
    -2.66%
    Biocon stock zooms 9% on Psoriasis drug approval from Japan, Jefferies rating upgrade
    Biocon stock zooms 9% on Psoriasis drug approval from Japan, Jefferies rating upgrade
    livemint
    Biocon shares rose 9% to 389, driven by positive developments including Japanese approval for its biosimilar Ustekinumab. Jefferies upgraded its rating to 'Hold' with a target of 400, citing favorable FDA status for its Bengaluru facility.
    Copy LinkShare onShare on Share on Share on
    Biocon Ltd. is trading above its 50 day SMA of 331.9
    Biocon shares surge 7.79% on approval of Ustekinumab biosimilar in Japan
    Business Line | 07 Jan 2025 1 more
    Biocon share rises 4% as arm gets Japan's PMDA approval for Psoriasis drug
    Business Standard | 07 Jan 2025
    logo
    Wockhardt Ltd.
    07 Jan 2025
    1324.70
    -2.52%
    Wockhardt Eyes Rs 400-Crore Revenue From Pneumonia Antibiotic Miqnaf
    Wockhardt Eyes Rs 400-Crore Revenue From Pneumonia Antibiotic Miqnaf
    NDTV Profit
    Miqnaf is an antibiotic for treatment of community-acquired bacterial pneumonia, including those caused by multi-drug resistant pathogens.
    Copy LinkShare onShare on Share on Share on
    Promoters pledged 1.26% of shares in last quarter. Total pledge stands at 18.24% of promoter holdings
    logo
    FDC Ltd.
    07 Jan 2025
    456.05
    1.20%
    Theatre stampede: Actor Allu Arjun visits injured boy in hospital
    Business Standard
    Top Telugu actor Allu Arjun on Tuesday visited the boy, who is undergoing treatment at a private hospital here after suffering serious injury in a stampede at the premiere of his latest film Pushpa 2. Earlier, Arjun scheduled to visit the hospital on January 5 but the plan was cancelled. The actor is added as accused No 11 in the case filed after a woman died and her eight-year-old son sustained serious injuries in the stampede on December 4. During Allu Arjun's visit to the hospital on Tuesday, Telangana State Film Development Corporation (FDC) Chairman Dil Raju was also present. Security was enhanced at the hospital in view of the actor's visit. The SHO of Ramgopalpet Police Station had issued a notice to Allu Arjun regarding his proposed visit to the hospital and advised him to keep it confidential so that public order could be maintained in and around the hospital. The SHO said police would make necessary arrangements for his visit. The 'Pushpa' actor had earlier said that he
    Copy LinkShare onShare on Share on Share on
    FDC Ltd. is trading below its 150 day SMA of 465.8
    logo
    Caplin Point Laboratories Ltd.
    07 Jan 2025
    2127.00
    -1.58%
    Caplin Point Labs Share Price Rises As US FDA Closes Inspection With Zero 483 Observations
    Caplin Point Labs Share Price Rises As US FDA Closes Inspection With Zero 483 Observations
    NDTV Profit
    Caplin Point Laboratories Ltd. share price rose 3.46% to Rs 2,594.95 apiece, the highest level since Jan 3.
    Copy LinkShare onShare on Share on Share on
    Caplin Point Laborat.. has an average target of 2400.00 from 1 broker.
    logo
    Dr. Reddy's Laboratories Ltd.
    07 Jan 2025
    1224.20
    0.43%
    Dr Reddy Share Price Live blog for 07 Jan 2025
    Dr Reddy Share Price Live blog for 07 Jan 2025
    livemint
    Dr Reddy Share Price Today Live Updates : Dr Reddy stock price went down today, 07 Jan 2025, by -0.16 %. The stock closed at 1352.75 per share. The stock is currently trading at 1350.65 per share. Investors should monitor Dr Reddy stock price closely in the coming days and weeks to see how it reacts to the news.
    Copy LinkShare onShare on Share on Share on
    Dr. Reddy's Laboratories Ltd. is trading above its 100 day SMA of 1211.6
    more
    loading
    Logo Trendlyne

    Stay ahead of the market

    Company

    PrivacyDisclaimerTerms of Use Contact Us

    Resources

    Blog FAQsStock Market Widgets

    Copyright © 2025 Giskard Datatech Pvt Ltd